ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) went down by -0.91% from its latest closing price when compared to the 1-year high value of $30.38 and move down -3.16%, while ACAD stocks collected +2.04% of gains with the last five trading sessions.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Worth an Investment?

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) The 36 Months beta value for ACAD stocks is at 2.74, while 8 of the analysts out of 12 who provided ratings for ACADIA Pharmaceuticals Inc. stocks as a “buy” while 0 as overweight, 4 rated it as hold and 0 as sell. The average price we get from analysts is $32.58 which is $3.13 above current price. ACAD currently has a short float of 9.34% and public float of 142.3M with average trading volume of 1.27M shares.

ACAD Market Performance

ACAD stocks went up by 2.04% for the week, with the monthly jump of 10.22% and a quarterly performance of 15.04%, while its annual performance rate touched 97.39%. The simple moving average for the period of the last 20 days is 11.68% for ACAD stocks with the simple moving average of 25.61% for the last 200 days.

Analysts’ Opinion on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Many brokerage firms have already submitted their reports for ACAD stocks, with Needham repeating the rating for ACAD shares by setting it to “Buy”. The predicted price for ACAD socks in the upcoming period according to Needham is $34 based on the research report published on July 23, 2019.

Canaccord Genuity, on the other hand, stated in their research note that they expect to see ACAD stock at the price of $23. The rating they have provided for ACAD stocks is “Hold” according to the report published on December 10, 2018.

Piper Jaffray gave “ Overweight” rating to ACAD stocks, setting the target price at $23 in the report published on September 21, 2018.

ACAD Stocks 12.36% Far from 50 Day Moving Average

After a stumble in the market that brought ACAD to its low price for the period of the last 52 weeks, ACADIA Pharmaceuticals Inc. was unable to take a rebound, for now settling with -3.06% of loss for the given period.

The stock volatility was left at 4.61%, however, within the period of a single month, the volatility rate increased by 3.65%, while the shares surge at the distance of +12.11% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +20.75% upper at the present time.

In the course of the last 5 trading sessions, ACAD went up by +2.04%, which changed the moving average for the period of 200 days to the total of +53.07% of gains for the stock in comparison to the 20-day moving average settled at $26.53. In addition, ACADIA Pharmaceuticals Inc. saw 82.13% in overturn over the period of a single year with a tendency to cut further gains.

ACAD Stock Insider Trading

Reports are indicating that there were more than several insider trading activities at ACADIA Pharmaceuticals Inc. (ACAD), starting from Brege Laura, who sold 10,000 shares at the price of $20.00 back on Jan 09. After this action, Rushing now owns 0 shares of ACADIA Pharmaceuticals Inc., valued at $200,041 with the latest closing price.

BAKER BROS. ADVISORS LP, the Director of ACADIA Pharmaceuticals Inc., bought 11,764,705 shares at the value of $17.00 during a trade that took place back on Nov 30, which means that BAKER BROS. ADVISORS LP is holding 35,976,940 shares at the value of $199,999,985 based on the most recent closing price.

ACAD Stock Fundamentals

The current profitability levels are settled at -110.56 for the present operating margin and +94.47 for gross margin. The net margin for ACADIA Pharmaceuticals Inc. stands at -109.56. Total capital return value is set at -60.77, while invested capital returns managed to touch -60.22. Equity return holds the value -71.00%, with -60.60% for asset returns.

The receivables turnover for ACADIA Pharmaceuticals Inc. is 9.68 with the total asset turnover at the value of 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.83.